Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.46 |
| ▸ | KDR | P35968 | 4/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 8/20 | 0.43 |
| ▸ | HTR2C | P28335 | 8/20 | 0.43 |
| ▸ | HTR2B | P41595 | 7/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12972364 | 0.89 | CSF1R (0.47) | ARKDRBRAFHTR2AHTR2C | |
| SCHEMBL2776752 | 0.86 | KDR (0.49) | KDRHTR2AHTR2CHTR2BCYP1A2 | |
| SCHEMBL2776954 | 0.85 | KDR (0.51) | KDRBRAFHTR2AHTR2CHTR2B | |
| SCHEMBL2782680 | 0.85 | HTR2C (0.42) | KDRBRAFHTR2AHTR2CHTR2B | |
| SCHEMBL2782677 | 0.85 | HTR2C (0.42) | KDRBRAFHTR2AHTR2CHTR2B | |
| SCHEMBL2778180 | 0.84 | HTR2C (0.47) | HTR2AHTR2CHTR2BCYP1A2CYP2C9 | |
| SCHEMBL2777686 | 0.84 | SRC (0.52) | KDRBRAFHTR2AHTR2CHTR2B | |
| SCHEMBL2777610 | 0.83 | HTR2C (0.44) | HTR2AHTR2CHTR2BCYP1A2CYP2C9 | |
| SCHEMBL2777572 | 0.83 | KDR (0.43) | KDRBRAFHTR2AHTR2CHTR2B | |
| SCHEMBL2778523 | 0.83 | RIPK1 (0.54) | KDRBRAFHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | AR 1269/4885KDR 479/4885BRAF 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.